Tempus AI/$TEM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Ticker
$TEM
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Employees
2,400
Website
Tempus AI Metrics
BasicAdvanced
$11B
-
-$4.92
-
-
Price and volume
Market cap
$11B
52-week high
$91.45
52-week low
$31.36
Average daily volume
9.7M
Financial strength
Current ratio
1.706
Quick ratio
1.431
Long term debt to equity
260.069
Total debt to equity
262.957
Interest coverage (TTM)
-12.10%
Profitability
EBITDA (TTM)
-658.21
Gross margin (TTM)
57.09%
Net profit margin (TTM)
-88.27%
Operating margin (TTM)
-87.96%
Effective tax rate (TTM)
6.08%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-43.89%
Return on equity (TTM)
10,560.77%
Valuation
Price to revenue (TTM)
11.561
Price to book
33.6
Price to tangible book (TTM)
-27.46
Price to free cash flow (TTM)
-43.666
Free cash flow yield (TTM)
-2.29%
Free cash flow per share (TTM)
-145.05%
Growth
Revenue change (TTM)
42.93%
Earnings per share change (TTM)
6.29%
Bulls say / Bears say
Tempus AI reported a 75% year-over-year revenue increase in Q1 2025, reaching $255.7 million, indicating strong demand for its offerings. (marketbeat.com)
The company secured a three-year, $200 million data licensing agreement with AstraZeneca and Pathos AI to develop oncology foundation models, enhancing its revenue streams. (bisoncoop.com)
Tempus AI's xT CDx assay received Advanced Diagnostic Laboratory Test (ADLT) status from CMS, with an initial reimbursement rate of $4,500, potentially boosting its financial performance. (tradingview.com)
Despite revenue growth, Tempus AI remains unprofitable, with a net loss of $68.0 million in Q1 2025 and ongoing cash burn. (marketbeat.com)
A short-seller report by Spruce Point Capital Management raised concerns about the company's financial reporting and partnerships, suggesting a potential stock price decline of 50% to 60%. (fool.com)
The company carries significant debt, with long-term debt reaching $800.8 million and a debt-to-equity ratio of 2.45x, increasing financial leverage and interest burden. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Tempus AI News
AllArticlesVideos
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
Business Wire·1 week ago
Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
Business Wire·4 weeks ago
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tempus AI stock?
Tempus AI (TEM) has a market cap of $11B as of July 25, 2025.
What is the P/E ratio for Tempus AI stock?
The price to earnings (P/E) ratio for Tempus AI (TEM) stock is 0 as of July 25, 2025.
Does Tempus AI stock pay dividends?
No, Tempus AI (TEM) stock does not pay dividends to its shareholders as of July 25, 2025.
When is the next Tempus AI dividend payment date?
Tempus AI (TEM) stock does not pay dividends to its shareholders.
What is the beta indicator for Tempus AI?
Tempus AI (TEM) does not currently have a Beta indicator.